Influencers on social media, including Facebook (META), Instagram, and YouTube (GOOGL), are talking up weight loss drugs, but are not always revealing the risks of taking this type of drug, Peter Loftus and Sara O’Brien of The Wall Street Journal report. The virtual word-of-mouth has convinced many to take the weight-loss drug, but side effects, such as painful headaches and vomiting, are often omitted or downplayed. Novo Nordisk’s (NVO) Ozempic and Wegovy as well as Eli Lilly’s (LLY) Mounjaro and Zepbound are the first of the weight-loss medicines to become social-media sensations.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on META:
- META Gains after Integrating AI into Its Apps
- EDPB: Meta should give users free option without targeted ads, Reuters reports
- JMP Securities tech/software analysts hold analyst/industry conference call
- #SocialStocks: Trump Media tumbles after share sale and streaming announcement
- Piper Sandler chief investment strategist holds analyst/industry conference call